Salute e Benessere

Coloplast A/S - Interim Financial Report, 9M 2024/25

Coloplast A/S - Interim Financial Report, 9M 2024/252024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin 1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment.Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%.Growth in...
Nasdaq GlobeNewswire
19/08/2025

12.6% CAGR for Cancer Drugs Market to Reach US$516.15 billion by 2031, Due to…

The burden is projected to increase by ~77% by 2050, further straining health systems and communities. According to the American Cancer Society, genes inherited from parents are responsible for 5–10% of all cancers. The highest rates are observed in Australia, North America, New Zealand, and Northern Europe, while mortality disproportionately affects low-HDI nations due to limited screening and access to care. The burden is projected to increase by ~77% by 2050, further straining health…
PR Newswire
19/08/2025

Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September…

Following the changes to the Executive Leadership Team, announced on 19.08.2025*, we are pleased to share with you the updated presenters list for our Capital Markets Day on 2 September 2025. For those of you who have signed up, we look forward to seeing you at the event. The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport) Ellehammersvej 20, 2770 Kastrup from 10.30 - 17.00 CEST(Central European Summer Time)The event will be held in...
Nasdaq GlobeNewswire
19/08/2025

LabConnect Launches LabConnector™ to Streamline Lab Data Integration

LabConnector is purpose-built for IT teams and data analysts at sponsor organizations who need streamlined, secure, and accurate laboratory data for ongoing clinical trials. With seamless integration to any LabConnect partner, it delivers unmatched flexibility for clinical operations and data management. LabConnector is purpose-built for IT teams and data analysts at sponsor organizations who need streamlined, secure, and accurate laboratory data for ongoing clinical trials. With seamless...
PR Newswire
19/08/2025

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated...
Nasdaq GlobeNewswire
19/08/2025

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for…

In the ongoing CLINCH Phase I/II clinical study, data show that ATG-022 demonstrated significant antitumor activity and a favorable safety profile in patients with gastric or gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression levels. In the ongoing CLINCH Phase I/II clinical study, data show thatATG-022 demonstrated significant antitumor activity and a favorable safety profile in patients with gastric or gastroesophageal junction adenocarcinoma across...
PR Newswire
19/08/2025

Zymeworks Announces Participation in Upcoming Investor Conferences

Citi’s Biopharma Back to School Conference: Zymeworks’ management will participate in one-on-one meetings on September 3 in Boston, MA.Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 4 at 4:30 pm Eastern Time (ET) in Boston, MA.Cantor Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 5 at 8:35 am ET in New York, NY.Morgan Stanley...
Nasdaq GlobeNewswire
19/08/2025

Monument Therapeutics Announces Partnership with Foundation for the National…

This Investigational New Drug (IND)-opening clinical trial for MT1988 is the first patient trial from Monument's precision medicine pipeline. The randomized, placebo-controlled study will enroll 150 CHR participants, who will receive one of two dose levels of MT1988 or placebo over an eight-week treatment period. The trial is on track to begin dosing in the autumn of 2025. This Investigational New Drug (IND)-opening clinical trial for MT1988 is the first patient trial from Monument's…
PR Newswire
19/08/2025

Dubai Humanitarian: Powerful New Documentary Reveals World's Largest…

- First six months of 2025 saw $48.8m humanitarian aid distributed from Dubai Humanitarian, reflected in its Humanitarian Logistics Databank - First six months of 2025 saw$48.8mhumanitarian aid distributed from Dubai Humanitarian, reflected in its Humanitarian Logistics Databank DUBAI, UAE, Aug. 19, 2025 /PRNewswire/ -- Dubai Humanitarian, the world's largest humanitarian logistics hub, has unveiled a new documentary, Coming Together: The Dubai Humanitarian Story- a gripping...
PR Newswire
19/08/2025

SciBase: Interim report

The second quarter in figures The second quarter in figures The first half-year in figures Important events during the quarter Important events after the end of the period This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August19, 2025 . This interim report has not been...
PR Newswire
19/08/2025

Coloplast A/S - Interim Financial Report, 9M 2024/25

2024/25Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin 1of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment.Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%.Growth in Ostomy Care was driven by broad-based contribution across...
Nasdaq GlobeNewswire
19/08/2025

Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes to…

Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, senior leaders from across the Coloplast Group have worked together to finalise the new Coloplast Group strategy, which will be communicated internally and externally in early September following approval by the Board of Directors.“Our new...
Nasdaq GlobeNewswire
19/08/2025

Basilea on track with strong 2025 half-year results

Cresemba ®and Zevtera ® -related revenues rise by 24% to CHF 90.5 millionTotal revenue grows significantly by 36% to CHF 104.0 millionOperating profit surges by 160% to CHF 24.0 millionOperating cash flow increases by 29% to CHF 23.1 millionFull-year 2025 guidance: on track and updated to reflect recent in-licensing of a novel oral phase 3-ready antibiotic Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, August 19, 2025 Basilea...
Nasdaq GlobeNewswire
19/08/2025

Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE®…

Pratteln, Switzerland , 19 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Sales are expected to begin on a named patient basis in Q1 2026, with broader commercial sales anticipated in late 2026...
Nasdaq GlobeNewswire
19/08/2025

Idorsia publishes end results of repurchase offer for its 2025 and 2028…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 19, 2025Idorsia Ltd (SIX: IDIA) announces the end results of the repurchase offer for its outstanding CHF 204 * million convertible bonds maturing in 2025 ( CB 2025 ; ISIN CH0426820350), and CHF 600 million convertible bonds maturing in 2028 ( CB 2028 ; ISIN CH1128004079) (theRepurchase Offer )launchedon June 25, 2025.As of the end of the additional acceptance period, Bondholders have accepted the...
Nasdaq GlobeNewswire
19/08/2025

Tigermed Receives MSCI ESG AAA Rating

Environmental:Tigermed has set science-based targets for reducing greenhouse gas emissions, which have been validated by the Science Based Targets initiative (SBTi). The company has implemented a comprehensive environmental management system, improved monitoring of emissions and resource utilization, and adopted digital platforms and green office initiatives to promote environmental sustainability. Environmental:Tigermed has set science-based targets for reducing greenhouse gas emissions,...
PR Newswire
19/08/2025

Anua Breaks into 650 'Boots' Stores in UK... "Cements K-Beauty Status in Europe"

Anua started with 120 stores when it first launched at Boots in October last year, and quickly expanded to 470 in March and 650 as of July. The number of stores has increased more than sixfold in nine months, establishing itself as a leading K-beauty brand with a robust distribution network across the UK in a short period of time. Anua started with 120 stores when it first launched at Boots in October last year, and quickly expanded to 470 in March and 650 as of July. The number of stores has...
PR Newswire
19/08/2025

CSL announces rise in full year net profit

Dr. Paul McKenzie, CSL's Chief Executive Officer and Managing Director said, "I am pleased to report another on-target result for the 2025 financial year, led by CSL Behring and continued strong demand for our life-saving plasma therapies. Dr.Paul McKenzie, CSL's Chief Executive Officer and Managing Director said, "I am pleased to report another on-target result for the 2025 financial year, led by CSL Behring and continued strong demand for our life-saving plasma therapies. "CSL…
PR Newswire
19/08/2025

TSLP Inhibitors Market Set for Significant Growth During the Forecast Period…

Key Takeaways from the TSLP Inhibitors Market Report Key Takeaways from the TSLP Inhibitors Market Report Discover which indication is expected to grab the major TSLP inhibitors market share @TSLP Inhibitors Market Report TSLP Inhibitors Market Dynamics The TSLP inhibitors market is gaining momentum asadvances in immunology and biologics manufacturingcreate new therapeutic opportunities. TSLP is increasingly recognized as a central upstream driver of type 2 inflammation,...
PR Newswire
18/08/2025

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and…

Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovationSAN DIEGO, Aug.18, 2025(GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also...
Nasdaq GlobeNewswire
18/08/2025

Nyxoah Reports Second Quarter Financial and Operating Results

REGULATED INFORMATIONNyxoah Reports Second Quarter Financial and Operating Results FDA Approves Genio® System for U.S. Market; Company Begins Commercial LaunchMont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating...
Nasdaq GlobeNewswire
18/08/2025

PCI Biotech announces discontinuation of development of the PCL technology and…

Today’s decision is primarily based on the insufficient progress towards the 2025 goal of demonstrating improved yield in mini benchtop bioreactors. Achieving successful end-to-end results in small bioreactors is a critical risk-reducing milestone for further development.Following the progress reported in the preliminary 2024 Interim Report (27 thFeb 2025) and the Annual Report 2024 (24 thApril 2025), additional initiatives were undertaken to demonstrate PCL’s capability to increase...
Nasdaq GlobeNewswire
18/08/2025

Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and…

About Northwest Biotherapeutics About Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax ® dendritic cell-based vaccines. The Company's lead program involves DCVax ® -L treatment...
PR Newswire
18/08/2025

Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7%…

Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today its financial results for the second quarter and six-month period ended June 30, 2025. Financial Highlights for the Three and Six Months Ended June 30, 2025Income StatementCosmos Health continued its positive trajectory in Q2 2025, delivering double-digit revenue growth of 11.66% and a 51.60% increase in gross profit...
Nasdaq GlobeNewswire
18/08/2025
Altri  Comunicati